ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes in patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), the efficacy of current TKIs for emerging ALK rearrangement subtypes warrants further investigation, particularly with the advancements in genomic sequencing technologies.
methodsWe retrospectively analyzed 118 NSCLC patients with ALK rearrangements identified by next-generation sequencing (NGS) from January 2015 to April 2024. Among these, 89 patients who received first-line ALK-TKIs were assessed to determine therapeutic outcomes based on ALK rearrangement subtypes.
resultsAmong 118 NSCLC patients, 36 (30.5%) harbored nonreciprocal/reciprocal translocations, 73 (61.9%) carried solitary EML4-ALK fusion, and 9 (7.6%) had solitary non-EML4-ALK fusions. Of the 89 patients treated with first-line TKIs, 60 (67.4%) had solitary 3'-ALK fusions, whereas 29 (32.6%) exhibited nonreciprocal/reciprocal ALK translocations. Compared with patients harboring solitary 3'-ALK fusions, those with nonreciprocal/reciprocal translocations experienced significantly shorter median progression-free survival (mPFS) (15.6 vs. 31.1 months; HR = 1.805; P = 0.048), although no significant difference in median overall survival (mOS) was observed (66.6 vs. 75.7 months; HR = 1.162; P = 0.714). Additionally, TP53 mutations were the most common co-occurring alterations in both groups, with no significant difference in frequency (P = 0.650).
conclusionsNonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.
Indexed as
Identifiers
41247418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.